| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/OXFORDJOURNALS.AJE.A116134 |
| P698 | PubMed publication ID | 1951266 |
| P2093 | author name string | Levine MM | |
| Prado V | |||
| Ferreccio C | |||
| Ojeda A | |||
| Abrego P | |||
| Guers L | |||
| Cayyazo M | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Chile | Q298 |
| diarrhea | Q40878 | ||
| acute diarrhea | Q12626662 | ||
| P1104 | number of pages | 14 | |
| P304 | page(s) | 614-627 | |
| P577 | publication date | 1991-09-01 | |
| P1433 | published in | American Journal of Epidemiology | Q4744243 |
| P1476 | title | Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile | |
| P478 | volume | 134 |
| Q33518017 | A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation |
| Q34992202 | A cohort study to define the age-specific incidence and risk factors of Shigella diarrhoeal infections in Vietnamese children: a study protocol |
| Q28767862 | A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology |
| Q38294781 | A murine antibody to Shigella dysenteriae type 1 employs V-genes that contain a rearranged codon for the λ light chain |
| Q37134267 | A review of changing episode definitions and their effects on estimates of diarrhoeal morbidity |
| Q40126474 | An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype. |
| Q37668395 | An update on vaccines against Shigella |
| Q34987921 | Appendectomy and Clostridium difficile colitis: relationships revealed by clinical observations and immunology |
| Q52337397 | Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex. |
| Q39519924 | Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection |
| Q33597022 | Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli |
| Q39963174 | Biennial hyperepidemic shigellosis in an observant Jewish community. |
| Q64114469 | Booster Vaccination With GVGH 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial |
| Q33495433 | Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. |
| Q35111449 | Changes in human ecology and behavior in relation to the emergence of diarrheal diseases, including cholera |
| Q37113756 | Changing trends and serotype distribution of Shigella species in Beijing from 1994 to 2010 |
| Q38776163 | Characterization of a multicomponent live, attenuated Shigella flexneri vaccine |
| Q34002298 | Characterization of pic, a secreted protease of Shigella flexneri and enteroaggregative Escherichia coli. |
| Q39713870 | Childhood diarrhoea symptoms, management and duration: observations from a longitudinal community study |
| Q92487093 | Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q74420507 | Conformational stabilization of the altruronic acid residue in the O-specific polysaccharide of Shigella sonnei/Plesiomonas shigelloides |
| Q91801457 | Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies |
| Q91801450 | Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays |
| Q34545910 | Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine |
| Q35804868 | Decreasing Shigellosis-related Deaths withoutShigellaspp.–specific Interventions, Asia |
| Q37643320 | Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. |
| Q55333715 | Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay. |
| Q35175673 | Diapers in war zones: ethnomedical factors in acute childhood gastroenteritis in Peshawar, Pakistan |
| Q33617990 | Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo |
| Q40622945 | Efficient Iterative Synthesis of O-Acetylated Tri- to Pentadecasaccharides Related to the Lipopolysaccharide of Shigella flexneri Type 3 a through Di- and Trisaccharide Glycosyl Donors |
| Q47231371 | Epidemiology of Shigella infections in two ethnic groups in a geographic region in southern Israel |
| Q45138749 | Epidemiology of highly endemic multiply antibiotic-resistant shigellosis in children in the Peruvian Amazon. |
| Q37032264 | Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. |
| Q36764372 | Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects |
| Q41581938 | Factors that explain excretion of enteric pathogens by persons without diarrhea |
| Q90631867 | Functional Annotation and Curation of Hypothetical Proteins Present in A Newly Emerged Serotype 1c of Shigella flexneri: Emphasis on Selecting Targets for Virulence and Vaccine Design Studies |
| Q36866917 | Genetic characterization of antimicrobial resistance of Shigella flexneri 1c isolates from patients in Egypt and Pakistan |
| Q34275969 | Global Illness and Deaths Caused by Rotavirus Disease in Children |
| Q34068059 | Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans |
| Q30452924 | High frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, streptomycin, chloramphenicol, and tetracycline isolated from patients with shigellosis in northeastern Brazil during the period 1988 to 1993. |
| Q30418588 | Housefly population density correlates with shigellosis among children in Mirzapur, Bangladesh: a time series analysis |
| Q99616552 | Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G |
| Q38952300 | Immunization of Mice with a Live Transconjugant Shigella Hybrid Strain Induced Th1 and Th17 Cell-Mediated Immune Responses and Confirmed Passive Protection Against Heterologous Shigellae. |
| Q40460000 | Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. |
| Q38648043 | In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity. |
| Q42067726 | Increased isolation and characterization of Shigella sonnei obtained from hospitalized children in Tehran, Iran |
| Q72678992 | Is protection against shigellosis induced by natural infection with Plesiomonas shigelloides? |
| Q39517102 | Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine |
| Q35598035 | Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit |
| Q41846692 | Molecular epidemiology of Shigella spp strains isolated in two different metropolitam areas of southeast Brazil |
| Q37163698 | Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production. |
| Q38114268 | Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate |
| Q51058305 | Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella. |
| Q34120926 | Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults |
| Q34748949 | Phenotypic and genotypic characterization of provisional serotype Shigella flexneri 1c and clonal relationships with 1a and 1b strains isolated in Bangladesh |
| Q34545082 | Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines |
| Q35924773 | Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB |
| Q37105553 | Progress and pitfalls in Shigella vaccine research |
| Q73507076 | Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition |
| Q78171100 | Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines |
| Q42227472 | Recent trends in the epidemiology of shigellosis in Israel |
| Q92968346 | Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development |
| Q38665950 | Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. |
| Q84554549 | Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers |
| Q102056730 | Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study |
| Q34006223 | Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel |
| Q36945836 | Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. |
| Q37175693 | Secretory IgA: arresting microbial pathogens at epithelial borders |
| Q91881906 | Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis |
| Q35225017 | Serum antibody to lipopolysaccharide antigens of Shigella species among U.S. military personnel deployed to Saudi Arabia and Kuwait during Operations Desert Shield and Desert Storm. |
| Q37477191 | Shigella Vaccine Development: Finding the Path of Least Resistance |
| Q33876179 | Shigella and Shiga toxin-producing Escherichia coli causing bloody diarrhea in Latin America |
| Q36920244 | Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. |
| Q42664186 | Shigella flexneri type-specific antigen V: cloning, sequencing and characterization of the glucosyl transferase gene of temperate bacteriophage SfV. |
| Q34202171 | Shigella isolates from the global enteric multicenter study inform vaccine development |
| Q56383780 | Shigellosis |
| Q34725902 | Shigellosis in neonates and young infants. |
| Q40087889 | Stable expression of Shigella dysenteriae serotype 1 O-antigen genes integrated into the chromosome of live Salmonella oral vaccine vector Ty21a |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q34000330 | Strategy for cross-protection among Shigella flexneri serotypes |
| Q33607442 | Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid |
| Q37194696 | Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates |
| Q26862724 | Systematic review of diarrhea duration and severity in children and adults in low- and middle-income countries |
| Q52657631 | T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans. |
| Q36412034 | The Global Enteric Multicenter Study (GEMS) of diarrheal disease in infants and young children in developing countries: epidemiologic and clinical methods of the case/control study |
| Q38909275 | The Orchestra and Its Maestro: Shigella's Fine-Tuning of the Inflammasome Platforms. |
| Q38035961 | The Shigella human challenge model |
| Q38753453 | The genomic signatures of Shigella evolution, adaptation and geographical spread |
| Q102056729 | The search for an efficacious shigella vaccine |
| Q39511268 | Thymic independence of adaptive immunity to the intracellular pathogen Shigella flexneri serotype 2a |
| Q34002272 | Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice |
| Q33876803 | Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 |
| Q40098097 | Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice |
| Q39217803 | Vaccines against cholera, typhoid fever and shigellosis for developing countries |
| Q33578045 | Vaccines against human diarrheal pathogens: current status and perspectives |
Search more.